GO
Loading...

Celgene Corp

More

  • Midday Glance: Biotechnology companies Tuesday, 24 Mar 2015 | 1:19 PM ET

    Amgen Inc. fell$. 06 or percent, to $166.48. Biogen Idec fell $4.40 or. 9 percent, to $459.34. Gilead Sciences Inc. rose $1.52 or 1.5 percent, to $101.78.

  • Final Glance: Biotechnology companies Monday, 23 Mar 2015 | 6:03 PM ET

    Amgen Inc. fell $3.56 or 2.1 percent, to $166.54. Biogen Idec fell $12.25 or 2.6 percent, to $463.73. Celgene Corp. fell $5.56 or 4.3 percent, to $122.94.

  • Midday Glance: Biotechnology companies Monday, 23 Mar 2015 | 1:32 PM ET

    Amgen Inc. fell $3.35 or 2.0 percent, to $166.75. Biogen Idec fell $11.26 or 2.4 percent, to $464.72. Celgene Corp. fell $4.92 or 3.8 percent, to $123.58.

  • Early Glance: Biotechnology companies Monday, 23 Mar 2015 | 10:12 AM ET

    Amgen Inc. fell $3.94 or 2.3 percent, to $166.16. Biogen Idec fell $7.09 or 1.5 percent, to $468.89. Celgene Corp. fell $4.67 or 3.6 percent, to $123.83.

  • Final Glance: Biotechnology companies Friday, 20 Mar 2015 | 8:00 PM ET

    Amgen Inc. rose$. 99 or. 6 percent, to $170.10. Biogen Idec rose $42.33 or 9.8 percent, to $475.98. Celgene Corp. rose $3.17 or 2.5 percent, to $128.50.

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • Midday Glance: Biotechnology companies Friday, 20 Mar 2015 | 1:25 PM ET

    Amgen Inc. rose$. 39 or. 2 percent, to $169.50. Biogen Idec rose $38.60 or 8.9 percent, to $472.25. Celgene Corp. rose $1.36 or 1.1 percent, to $126.69.

  • Early Glance: Biotechnology companies Friday, 20 Mar 2015 | 10:19 AM ET

    Amgen Inc. rose $1.93 or 1.1 percent, to $171.04. Biogen Idec rose $29.86 or 6.9 percent, to $463.51. Celgene Corp. rose $1.29 or 1.0 percent, to $126.62.

  • Midday Glance: Biotechnology companies Thursday, 19 Mar 2015 | 2:00 PM ET

    Amgen Inc. rose $1.24 or. 7 percent, to $167.78. Biogen Idec rose $7.84 or 1.8 percent, to $435.77. Celgene Corp. rose $2.16 or 1.8 percent, to $124.84.

  • Early Glance: Biotechnology companies Thursday, 19 Mar 2015 | 10:22 AM ET

    Amgen Inc. rose $1.31 or. 8 percent, to $167.85. Biogen Idec rose $9.78 or 2.3 percent, to $437.71. Celgene Corp. rose $2.07 or 1.7 percent, to $124.75.

  • Drugs and money: Betting big on a biotech giant Tuesday, 10 Mar 2015 | 12:03 PM ET
    medicare.jpg

    One trader is betting big that Celgene will soar in the next few days. How big?

  • Lightning Round: This group goes higher tomorrow Wednesday, 25 Feb 2015 | 7:29 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: Where's the Nasdaq bubble? Monday, 23 Feb 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    As Apple hits new highs, "Mad Money" host Jim Cramer is betting on it to lift the Nasdaq.

  • Lightning Round: Don't listen to this CEO Monday, 23 Feb 2015 | 6:50 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer: We're in a bubble. So, what? Apple's cheap Monday, 23 Feb 2015 | 6:19 PM ET

    The market is reaching new highs, but could we really be in a bubble? Jim Cramer finds out.

  • Feb 23- The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. Farydak was approved for use in combination with Takeda Pharmaceutical Co Ltd's Velcade and...

  • Lightning Round: I'm putting my chips on this Tuesday, 17 Feb 2015 | 7:31 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: Nasdaq isn't worth worrying about Tuesday, 17 Feb 2015 | 7:16 PM ET
    Jim Cramer on Mad Money.

    'Mad Money' host Jim Cramer is putting overvaluation talk to the test.

  • Inside Celgene's ecosystem : CEO   Friday, 13 Feb 2015 | 6:33 AM ET
    Inside Celgene's ecosystem : CEO

    Robert Hugin, Celgene chairman & CEO, discusses his company's outlook, pipeline, and breakthrough treatments for cancer and other diseases.

  • Lightning Round: It's part of a major revolution Thursday, 12 Feb 2015 | 7:19 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.